Prostate Cancer Reports
54

Volume 6 Number 6
June 2018

.

Home > Prostate Cancer Reports > Volume 6, Year 2018 > Number 6, June



CONTENTS



DIAGNOSIS
EPIDEMIOLOGY, RISK FACTORS, PREVENTION
ETIOLOGY, PATHOGENESIS, PATHOLOGY
FOLLOW-UP, QUALITY OF LIFE
INTEGRATIVE MEDICINE
PROGNOSIS
TREATMENT





DIAGNOSIS

.

Borofsky S, George AK, Gaur S, Bernardo M, Greer MD, Mertan FV, Taffel M, Moreno V, Merino MJ, Wood BJ, Pinto PA, Choyke PL, Turkbey B.
What Are We Missing? False-Negative Cancers at Multiparametric MR Imaging of the Prostate.
Radiology. 2018 Jan;286(1):186-195. doi: 10.1148/radiol.2017152877. Epub 2017 Oct 20.
Source | Abstract | Full text | Similar articles



.

De Bari B, Mazzola R, Aiello D, Fersino S, Gregucci F, Alongi P, Nicodemo M, Cavalleri S, Salgarello M, Alongi F.
Could 68-Ga PSMA PET/CT become a new tool in the decision-making strategy of prostate cancer patients with biochemical recurrence of PSA after radical prostatectomy? A preliminary, monocentric series.
Radiol Med. 2018 Apr 23. doi: 10.1007/s11547-018-0890-7. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



.

Eissa A, El Sherbiny A, Coelho RF, Rassweiler J, Davis JW, Porpiglia F, Patel VR, Prandini N, Micali S, Sighinolfi MC, Puliatti S, Rocco B, Bianchi G.
The role of 68Ga-PSMA PET/CT scan in biochemical recurrence after primary treatment for prostate cancer: a systematic review of literature.
Minerva Urol Nefrol. 2018 Apr 17. doi: 10.23736/S0393-2249.18.03081-3. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



.

Han S, Woo S, Kim YJ, Suh CH.
Impact of 68Ga-PSMA PET on the Management of Patients with Prostate Cancer: A Systematic Review and Meta-analysis.
Eur Urol. 2018 Apr 18. pii: S0302-2838(18)30248-3. doi: 10.1016/j.eururo.2018.03.030. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



.

Lopci E, Guazzoni G, Lazzeri M.
68Ga Prostate-specific Membrane Antigen PET/CT for Primary Diagnosis of Prostate Cancer: Complementary or Alternative to Multiparametric MR Imaging.
Radiology. 2018 May;287(2):725-726. doi: 10.1148/radiol.2017172607.
Source | Abstract | Full text | Similar articles



.

Malik D, Kumar R, Mittal BR, Singh H, Bhattacharya A, Singh SK.
68Ga-Labeled PSMA Uptake in Nonprostatic Malignancies: Has the Time Come to Remove "PS" From PSMA?
Clin Nucl Med. 2018 Apr 23. doi: 10.1097/RLU.0000000000002103. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



.

Morris MJ.
The timing of molecular imaging in prostate cancer.
Clin Adv Hematol Oncol. 2018 Mar;16(3):195-197.
Source | Abstract | Full text | Similar articles



.

Soydal C, Urun Y, Suer E, Nak D, Ozkan E, Kucuk ON.
PSA levels as a predictor of 68Ga PSMA PET/CT positivity in patients with prostate cancer?
Q J Nucl Med Mol Imaging. 2018 May 10. doi: 10.23736/S1824-4785.18.03056-X. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



.

von Eyben FE, Baumann GS, Baum RP.
PSMA diagnostics and treatments of prostate cancer become mature.
Clin Transl Imaging. 2018;6(2):145-148. doi: 10.1007/s40336-018-0270-2. Epub 2018 Mar 7.
Source | Abstract | Full text | Similar articles



EPIDEMIOLOGY, RISK FACTORS, PREVENTION

.

Vartolomei MD, Kimura S, Ferro M, Foerster B, Abufaraj M, Briganti A, Karakiewicz PI, Shariat SF.
The impact of moderate wine consumption on the risk of developing prostate cancer.
Clin Epidemiol. 2018 Apr 17;10:431-444. doi: 10.2147/CLEP.S163668. eCollection 2018.
Source | Abstract | Full text | Similar articles



ETIOLOGY, PATHOGENESIS, PATHOLOGY

.

Abate-Shen C.
Prostate Cancer Metastasis - Fueled by Fat?
N Engl J Med. 2018 Apr 26;378(17):1643-1645. doi: 10.1056/NEJMcibr1800808.
Comment on: Tannert C et al, Prenatal Correction of X-Linked Hypohidrotic Ectodermal Dysplasia. N Engl J Med. 2018 Apr 26.
Source | Abstract | Full text | Similar articles



.

Schneider H, Faschingbauer F, Schuepbach-Mallepell S, Körber I, Wohlfart S, Dick A, Wahlbuhl M, Kowalczyk-Quintas C, Vigolo M, Kirby N, Tannert C, Rompel O, Rascher W, Beckmann MW, Schneider P.
Prenatal Correction of X-Linked Hypohidrotic Ectodermal Dysplasia.
N Engl J Med. 2018 Apr 26;378(17):1604-1610. doi: 10.1056/NEJMoa1714322.
Source | Abstract | Full text | Similar articles



.

Zhen JT, Syed J, Nguyen KA, Leapman MS, Agarwal N, Brierley K, Llor X, Hofstatter E, Shuch B.
Genetic testing for hereditary prostate cancer: Current status and limitations.
Cancer. 2018 Apr 18. doi: 10.1002/cncr.31316. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



FOLLOW-UP, QUALITY OF LIFE

.

Expert Panel on Urologic Imaging:, Froemming AT, Verma S, Eberhardt SC, Oto A, Alexander LF, Allen BC, Coakley FV, Davis BJ, Fulgham PF, Hosseinzadeh K, Porter C, Sahni VA, Schuster DM, Showalter TN, Venkatesan AM, Wang CL, Remer EM.
ACR Appropriateness Criteria® Post-treatment Follow-up Prostate Cancer.
J Am Coll Radiol. 2018 May;15(5S):S132-S149. doi: 10.1016/j.jacr.2018.03.019.
Source | Abstract | Full text | Similar articles



.

Tyson MD 2nd, Koyama T, Lee D, Hoffman KE, Resnick MJ, Wu XC, Cooperberg MR, Goodman M, Greenfield S, Hamilton AS, Hashibe M, Paddock LE, Stroup A, Chen V, Conwill R, McCollum D, Penson DF, Barocas DA.
Effect of Prostate Cancer Severity on Functional Outcomes After Localized Treatment: Comparative Effectiveness Analysis of Surgery and Radiation Study Results.
Eur Urol. 2018 Feb 28. pii: S0302-2838(18)30119-2. doi: 10.1016/j.eururo.2018.02.012. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



.

van Stam MA, van der Poel H.
The New Standard: Personalised Information about the Risks and Benefits of Treatment Strategies for Localised Prostate Cancer.
Eur Urol. 2018 Apr 13. pii: S0302-2838(18)30199-4. doi: 10.1016/j.eururo.2018.03.018. [Epub ahead of print]
Comment on: Tyson MD 2nd et al., Effect of Prostate Cancer Severity on Functional Outcomes After Localized Treatment: Comparative Effectiveness Analysis of Surgery and Radiation Study Results. Eur Urol. 2018 Feb 28.
Source | Abstract | Full text | Similar articles



INTEGRATIVE MEDICINE

.

Allott EH, Farnan L, Steck SE, Song L, Arab L, Su LJ, Fontham ETH, Mohler JL, Bensen JT.
Statin use, high cholesterol and prostate cancer progression; results from HCaP-NC.
Prostate. 2018 May 1. doi: 10.1002/pros.23644. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



.

Steck SE, Omofuma OO, Su LJ, Maise AA, Woloszynska-Read A, Johnson CS, Zhang H, Bensen JT, Fontham ETH, Mohler JL, Arab L.
Calcium, magnesium, and whole-milk intakes and high-aggressive prostate cancer in the North Carolina-Louisiana Prostate Cancer Project (PCaP).
Am J Clin Nutr. 2018 May 1;107(5):799-807. doi: 10.1093/ajcn/nqy037.
Source | Abstract | Full text | Similar articles



PROGNOSIS

.

Abdel-Rahman O.
Dissecting the heterogeneity of localized prostate cancer risk groups through integration of percent of positive cores.
Future Oncol. 2018 May 10. doi: 10.2217/fon-2017-0596. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



.

Kamel MH, Khalil MI, Alobuia WM, Su J, Davis R.
Incidence of metastasis and prostate-specific antigen levels at diagnosis in Gleason 3+4 versus 4+3 prostate cancer.
Urol Ann. 2018 Apr-Jun;10(2):203-208. doi: 10.4103/UA.UA_124_17.
Source | Abstract | Full text | Similar articles



.

Liu C, Liu T, Zhang N, Liu Y, Li N, Du P, Yang Y, Liu M, Gong K, Yang X, Zhu H, Yan K, Yang Z.
68Ga-PSMA-617 PET/CT: a promising new technique for predicting risk stratification and metastatic risk of prostate cancer patients.
Eur J Nucl Med Mol Imaging. 2018 May 2. doi: 10.1007/s00259-018-4037-9. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



.

Patel HD, Gupta M, Tosoian JJ, Carter HB, Partin AW, Epstein JI.
Subtyping the Risk of Intermediate-Risk Prostate Cancer for Active Surveillance Based on Adverse Pathology at Radical Prostatectomy.
J Urol. 2018 Apr 16. pii: S0022-5347(18)42985-0. doi: 10.1016/j.juro.2018.04.058. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



TREATMENT

.

Ávila M, Patel L, López S, Cortés-Sanabria L, Garin O, Pont À, Ferrer F, Boladeras A, Zamora V, Fosså S, Storås AH, Sanda M, Serra-Sutton V, Ferrer M.
Patient-reported outcomes after treatment for clinically localized prostate cancer: A systematic review and meta-analysis.
Cancer Treat Rev. 2018 May;66:23-44. doi: 10.1016/j.ctrv.2018.03.005. Epub 2018 Apr 2.
Source | Abstract | Full text | Similar articles



.

Higano CS.
Does nonmetastatic castration-resistant prostate cancer still exist?
Nat Rev Clin Oncol. 2018 Jun;15(6):350-351. doi: 10.1038/s41571-018-0025-z. Epub 2018 Apr 23.
Source | Abstract | Full text | Similar articles



.

Klotz L, Shayegan B, Guillemette C, Collins LL, Gotto G, Guérette D, Jammal MP, Pickles T, Richard PO, Saad F.
Testosterone suppression in the treatment of recurrent or metastatic prostate cancer - A Canadian consensus statement.
Can Urol Assoc J. 2018 Feb;12(2):30-37. doi: 10.5489/cuaj.5116. Epub 2017 Dec 19.
Source | Abstract | Full text | Similar articles



.

Luzzago S, Musi G, Catellani M, Russo A, Di Trapani E, Mistretta FA, Bianchi R, Cozzi G, Conti A, Pricolo P, Ferro M, Matei DV, Mirone V, Petralia G, de Cobelli O.
Multiparametric Magnetic-Resonance to Confirm Eligibility to an Active Surveillance Program for Low-Risk Prostate Cancer: Intermediate Time Results of a Third Referral High Volume Centre Active Surveillance Protocol.
Urol Int. 2018 May 7:1-9. doi: 10.1159/000488772. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



.

Miyahira AK, Pienta KJ, Morris MJ, Bander NH, Baum RP, Fendler WP, Goeckeler W, Gorin MA, Hennekes H, Pomper MG, Sartor O, Tagawa ST, Williams S, Soule HR.
Meeting report from the Prostate Cancer Foundation PSMA-directed radionuclide scientific working group.
Prostate. 2018 May 1. doi: 10.1002/pros.23642. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



.

Nevedomskaya E, Baumgart SJ, Haendler B.
Recent Advances in Prostate Cancer Treatment and Drug Discovery.
Int J Mol Sci. 2018 May 4;19(5). pii: E1359. doi: 10.3390/ijms19051359.
Source | Abstract | Full text | Similar articles



.

Rodriguez‑Moreno JF, Garcia‑Donas J.
Metastatic Prostate Cancer.
N Engl J Med. 2018 Apr 26;378(17):1653. doi: 10.1056/NEJMc1803343.
Comment on: Sartor O, de Bono JS, Metastatic Prostate Cancer, N Engl J Med. 2018 Feb 15.
Source | Abstract | Full text | Similar articles



.

Sartor O, de Bono JS.
Metastatic Prostate Cancer.
N Engl J Med. 2018 Apr 26;378(17):1653-1654. doi: 10.1056/NEJMc1803343.
Response to: Rodriguez‑Moreno JF, Garcia‑Donas J (N Engl J Med. 2018 Apr 26).
Source | Abstract | Full text | Similar articles



.

Sartor O, de Bono JS.
Metastatic Prostate Cancer.
N Engl J Med. 2018 Feb 15;378(7):645-657. doi: 10.1056/NEJMra1701695. Epub 2018 Feb 7.
Source | Abstract | Full text | Similar articles



.

Walz J.
Re: Surveillance or Metastasis-directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial.
Eur Urol. 2018 Apr 18. pii: S0302-2838(18)30255-0. doi: 10.1016/j.eururo.2018.03.037.
Source | Abstract | Full text | Similar articles